Cargando…

Desmopressin in moderate hemophilia A patients: a treatment worth considering

Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response, therefore, desmopressin is less frequently used in moderate hemophi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loomans, Janneke I., Kruip, Marieke J.H.A., Carcao, Manuel, Jackson, Shannon, van Velzen, Alice S., Peters, Marjolein, Santagostino, Elena, Platokouki, Helen, Beckers, Erik, Voorberg, Jan, van der Bom, Johanna G., Fijnvandraat, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830393/ https://www.ncbi.nlm.nih.gov/pubmed/29305412 http://dx.doi.org/10.3324/haematol.2017.180059

Ejemplares similares

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner
por: Loomans, Janneke I, et al.
Publicado: (2018)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis
por: Abdi, A., et al.
Publicado: (2020)

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
por: Oomen, Ilja, et al.
Publicado: (2022)

Desmopressin testing in von Willebrand disease: Lowering the burden
por: Heijdra, Jessica M., et al.
Publicado: (2022)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

A model worth considering?
por: Petsko, Gregory A
Publicado: (2006)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
por: Male, Christoph, et al.
Publicado: (2020)

Outpatient total knee arthroplasty: is it worth considering?
por: Rodríguez-Merchán, E. Carlos
Publicado: (2020)

Is It Worth Considering Colonic Evaluation After Appendicectomy?
por: Rajebhosale, Ramprasad P, et al.
Publicado: (2023)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study
por: van Velzen, Alice S., et al.
Publicado: (2020)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Prominent Mutation of Intron 22 Inversion in Sporadic Hemophilia: Is It Worth the Antenatal Screening?
por: Sasanakul, Werasak, et al.
Publicado: (2022)

Analgesia without sedatives during colonoscopies: worth considering?
por: Eberl, S., et al.
Publicado: (2012)

Is It worth Considering Circulating microRNAs in Multiple Sclerosis?
por: Jagot, Ferdinand, et al.
Publicado: (2016)

Some Points Worth Considering in the Treatment of Acute Gonorrhea
por: Senftenberg, B. F., et al.
Publicado: (1908)

Workplace-based licensing assessments: an idea worth considering?
por: Hatala, Rose, et al.
Publicado: (2022)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
por: van Balen, Erna C., et al.
Publicado: (2022)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Comparative response of Desmopressin versus Combination Therapy (Desmopressin + Oxybutynin) in Children with Nocturnal Enuresis
por: Kazi, Asiya, et al.
Publicado: (2020)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Heat shock proteins: a therapeutic target worth to consider
por: Dubey, Amita, et al.
Publicado: (2015)

Why the hypothesis of psychological mechanisms in long COVID is worth considering
por: Lemogne, Cédric, et al.
Publicado: (2023)

Antifibrinolytic Agents: Aprotinin, and Desmopressin
por: Bajaj, Pramila
Publicado: (2009)

Desmopressin Acetate in Intracranial Haemorrhage
por: Kapapa, Thomas, et al.
Publicado: (2014)

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
por: Dover, Saunya, et al.
Publicado: (2021)

Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis
por: Kamperis, Konstantinos, et al.
Publicado: (2016)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial
por: Ghanavati, Parvin Mousavi, et al.
Publicado: (2020)

Renal Medullary Carcinoma is a Diagnosis Worth Considering: Case Report
por: Thomas, Christopher, et al.
Publicado: (2010)

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
por: Isfordink, Cas J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lsq9t976dd9lf3nnlagn9sj28o